1From the dust:extracellular vesicles as regulators of development and neuroregenerationLeon G.Coleman JrPerspectives933-934
2Targeting epidermal growth factor receptor signaling to facilitate cortical injury repair?Ricardo Gómez-Oliva，Pedro Nunez-Abades，Carmen CastroPerspectives935-936
3Beyond functional MRI signals:molecular and cellular modifiers of the functional connectome and cognitionLorenzo Pini，Alessandro Salvalaggio，Maurizio CorbettaPerspectives937-938
4Alpha7 nicotinic receptors as potential theranostic targets for experimental strokeMaider Garbizu，Laura Aguado，Abraham MartínPerspectives939-940
5Targeting autophagy by polyphenols to prevent glycative stress-toxicity in the brainAlejandro Ponce-Mora，Eloy BejaranoPerspectives941-942
6Neurological consequences of human calmodulin mutationsHelene H.Jensen，Anders OlsenPerspectives943-944
7Does photobiomodulation require glucose to work effectively?Jaimie Hoh Kam，John MitrofanisPerspectives945-946
8Perspectives in human brain plasticity sparked by glioma invasion:from intraoperative (re)mappings to neural reconfigurationsSam Ng，Hugues Duffau，Guillaume HerbetPerspectives947-948
9Anti-aquaporin-4 antibody(AQP4-IgG)and anti-myelin oligodendrocyte glycoprotein antibody(MOG-IgG)in the cerebrospinal fluidTetsuya Akaishi，Tatsuro MisuPerspectives949-950
10Autophagy in neuroinflammation after traumatic brain injuryChinmoy Sarkar，Marta M.LipinskiPerspectives951-952
11Use of induced pluripotent stem cell-derived brain cells,organoids,assembloids,and blood-brain barrier models in understanding alcohol and anesthetic-induced brain injuries:an emerging perspectiveXiaowen BaiPerspectives953-954
12TDP-43 is a key molecule accelerating development of Alzheimer's disease following traumatic brain injuryChu ChenPerspectives955-956
13Role of lysosomal trafficking regulator in autophagic lysosome reformation in neurons:a disease perspectivePrashant Sharma，Jenny Serra-Vinardell，Wendy J.Introne，May Christine V.MalicdanPerspectives957-958
14Soluble alpha-synuclein post-translational modifications:unexpected regulators of pathological alpha-synuclein amplificationSimran Kapila，Yuhan Sun，Chao Peng，Shujing ZhangPerspectives959-960
15New insights into the effects of APP gene dose on synapse in Down syndromeXu-Qiao Chen，Xinxin ZuoPerspectives961-962
16Disentangling brain PrPC proteoforms and their roles in physiology and diseaseIlaria Vanni，Nonno RomoloPerspectives963-965
17Phosphorylation-driven aggregative proteins in neurodegenerative diseases:implications and therapeuticsAlba Espargaró，Raimon SabatePerspectives966-968
18Perspectives for delivery of therapeutics by extravasation of biodegradable microspheres in the brainAnne-Eva van der Wijk，Ed VanBavelPerspectives969-970
19Mitochondria replacement from transplanted amniotic fluid stem cells:a promising therapy for non-neuronal defects in spinal muscular atrophyMichela Pozzobon，Camilla BeanPerspectives971-972
20Is GDNF to Parkinson's disease what BDNF is to Huntington's disease?Francesca R.Fusco，Emanuela PaldinoPerspectives973-974
